References
- Petty RE, Southwood TT, Manners P, et al. International League of Associations for Rheumatology classification of juvenile arthritis: second revision. Arthritis Rheum. 2004;59:51–58.
- Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. [Internet]. 2012;71:1437–1439. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22679300
- Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–482. Hoboken.
- Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. [Internet]. 2005;352:1655–1666. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15843668
- Burgos-Vargas R, Vázquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61:941–942.
- Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. [Internet]. 2015;34:1839–1846. Available from: https://doi.org/10.1007/s10067-015-3029-4
- Davies R, Gaynor D, Hyrich KL, et al. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Semin Arthritis Rheum. [Internet]. 2017;46:584–593. Available from. : http://dx.doi.org/10.1016/j.semarthrit.2016.10.008
- Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–820.
- Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res. (Hoboken). [Internet]. 2019;71:717–734. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31021516
- Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. [Internet]. 2011;70:1605–1612. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21623000
- Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. [Internet]. 2012;64:2012–2021. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22183975
- Start time optimization of biologics in polyarticular JIA - full text view. ClinicalTrials.gov [Internet]. [cited 2019 Sep 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02593006.
- Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. Internet]. 2014;2:288–294. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24764575
- Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. (London, England) [Internet]. 2007;369:767–778. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17336654
- Schmeling H, Horneff G, Benseler SM, et al. Pharmacogenetics: can genes determine treatment efficacy and safety in JIA? Nat Rev Rheumatol. 2014;10:682–690. Nature Publishing Group.
- Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med. [Internet]. 2000;342:763–769. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10717011
- Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638–1644.
- Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. [Internet]. 2009;60:2794–2804. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19714630
- Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology. (Oxford). [Internet]. 2011;50:189–195. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21047801
- Horneff G, De Bock Foeldvari FI, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. [Internet]. 2009;68:519–525. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18413440
- Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. [Internet]. 1997;40:1202–1209. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9214419
- Horneff G, Foeldvari I, Minden K, et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol. (Hoboken, N.J.) [Internet]. 2015;67:2240–2249. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891010
- Hugle B, Burgos-Vargas R, Inman R, et al. Long-term outcome of anti-tumour necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol. [Internet]. 2014;32:424–431. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L373236611
- Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. [Internet]. 2017 cited 2020 Jan 7;19:256. Available from: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1462-2
- Klotsche J, Niewerth M, Haas J-P, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. [Internet]. 2016 cited 2019 Sep 16;75:855–861. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25926155
- Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology. (Oxford). [Internet]. 2007;46:1015–1019. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17403710
- Verazza S, Davì S, Consolaro A, et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol. 2016;14:68.
- Prince FHM, Twilt M, Ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. [Internet]. 2009;68:635–641. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18413443
- Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf [Internet]. 2015;14:1111–1126. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26084637
- Smith JA, Thompson DJS, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Care Res. 2005;53:18–23.
- Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.
- Marino A, Giani T, Cimaz R. Risks associated with use of TNF inhibitors in children with rheumatic diseases. Expert Rev Clin Immunol. 2019;15:189–198. Taylor and Francis Ltd.
- Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev. [Internet]. 2003;2:346–357. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14550876
- Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J Exp Med. 2016;213:1241–1253.
- Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr. [Internet]. 2006;149:572–575. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17011337
- Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. (Oxford). [Internet]. 2008;47:339–344. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18238789
- Simonini G, Druce K, Cimaz R, et al. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res. (Hoboken). [Internet]. 2014;66:1073–1084. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24740981
- Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. [Internet]. 2018;77:1003–1011. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29275333
- Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637–1646.
- Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. [Internet]. 2008;117:244–279. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18155297
- Taddio A, Cattalini M, Simonini G, et al. Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2016;12:641–649. Taylor and Francis Ltd.
- Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. [Internet]. 2007;56:3096–3106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17763439
- Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. [Internet]. 2010;69:718–722. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20237125
- Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology. (Oxford). [Internet]. 2008;47:1510–1514. Available from: : http://www.ncbi.nlm.nih.gov/pubmed/18676502
- Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74–79.
- Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis network. Arthritis Rheumatol. [Internet]. 2016 cited 2020 Jan 7;68:1522–1530. Available from: http://doi.wiley.com/10.1002/art.39667
- Poddighe D, Romano M, Gattinara M, et al. Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem. 2018;25:1–34.
- Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. [Internet]. 2018;77:21–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28507219
- Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology. [Internet]. 2015;23:71–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25687751
- Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor$α$. Inflamm Bowel Dis. 2013;19:1224–1231.
- Pediatric arthritis study of certolizumab pegol. ClinicalTrials.gov [Internet]. [cited 2019 Oct 15]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01550003.
- Giancane G, Consolaro A, Lanni S, et al. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. [Internet]. 2016 [cited 2019 Sep 1];3:187–207. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27747582
- Akioka S. Interleukin-6 in juvenile idiopathic arthritis. Mod Rheumatol. [Internet]. 2019 [cited 2019 Sep 28];29:275–286. Available from: https://www.tandfonline.com/doi/full/10.1080/14397595.2019.1574697
- European Medicines Agency. RoActemra, INN-tocilizumab [Internet]. [cited 2019 Sep 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf.
- Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. [Internet]. 2016 [cited 2019 Sep 22];43:2183–2188. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27633821
- Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. [Internet]. 2008 [cited 2019 Sep 28];371:998–1006. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18358927
- De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. [Internet]. 2012 [cited 2019 Sep 28];367:2385–2395. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23252525
- Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. [Internet]. 2012 [cited 2019 Sep 28];64:2773–2780. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22569881
- Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. [Internet]. 2012 [cited 2019 Sep 28];22:109–115. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21667343
- Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. [Internet]. 2015 cited 2019 Sep 28;17:66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26385753
- Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. [Internet]. 2017 cited 2019 Sep 28;16:493–500. Available from: https://www.tandfonline.com/doi/full/10.1080/14740338.2017.1303479
- Kawada J, Kitagawa Y, Iwata N, et al. Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab. Mod Rheumatol. [Internet]. 2013 cited 2019 Sep 28;23:972–976. Available from: http://www.tandfonline.com/doi/full/10.3109/s10165-012-0780-0
- Kawada J, Iwata N, Kitagawa Y, et al. Prospective monitoring of Epstein–Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab. Mod Rheumatol. [Internet]. 2012 [cited 2019 Sep 28];22:565–570. Available from: http://www.tandfonline.com/doi/full/10.3109/s10165-011-0552-2
- Beukelman T, Xie F, Baddley JW, et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. [Internet]. 2013 [cited 2019 Sep 28];65:1384–1389. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23460423
- Pfeil J, Grulich-Henn J, Wenning D, et al. Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab. Rheumatology. [Internet]. 2014 [cited 2020 Jan 19];53:1713–1714. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/keu032
- De Benedetti F, Schneider R, Weitzman S, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Pediatr Rheumatol. 2014;12(S1):P55.
- Kessler EA, Vora SS, Verbsky JW. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol. [Internet]. 2012 [cited 2019 Sep 28];10:30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22931129
- Vanoni F, Minoia F, Malattia C. Biologics in juvenile idiopathic arthritis: a narrative review. Eur J Pediatr. 2017;176:1147–1153.
- Giles J, Sattar N, Gabriel S. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial - ACR meeting abstracts [Internet]. ACR/ARHP Annu Meet. 2016 [cited 2020 Jan 9]. Available from: https://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/
- Yasuoka R, Iwata N, Abe N, et al. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Mod Rheumatol. [Internet]. 2019 cited 2019 Sep 28;29:324–327. Available from: https://www.tandfonline.com/doi/full/10.1080/14397595.2018.1457490
- Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. [Internet]. 2012 cited 2019 Sep 28;4:387–397. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23227116
- Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. [Internet]. 2004;31:2071–2075. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15468378
- Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. [Internet]. 2005;32:935–942. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15868633
- Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–1101.
- European Medicines Agency. Kineret. INN-Anakinra [Internet]. [cited 2019 Sep 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf
- Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. [Internet]. 2014 cited 2019 Sep 29;66:1034–1043. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24757154
- Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. [Internet]. 2008 [cited 2019 Sep 29];58:1505–1515. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18438814
- Ter Haar NM, Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin‐1 receptor antagonist as first‐line monotherapy in new‐onset systemic juvenile idiopathic arthritis: results from a five‐year follow‐up study. Arthritis Rheumatol. [Internet]. 2019 [cited 2019 Sep 29];71:1163–1173. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30848528
- Pardeo M, Bracaglia C, Tulone A, et al. Early treatment with anakinra in systemic juvenile idiopathic arthritis. ACR/ARP Annu Meet. [Internet]. BMJ Publishing Group Ltd and European League Against Rheumatism; 2019 [cited 2019 Sep 29]. p. 100.1–100. Available from: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2019-eular.5107
- European Medicines Agency. Ilaris. INN-Canakinumab[Internet]. [cited 2019 Sep 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf.
- Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. [Internet]. 2012 [cited 2019 Sep 29];64:557–567. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21953497
- Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. [Internet]. 2012 [cited 2019 Sep 29];367:2396–2406. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23252526
- Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. [Internet]. 2018 [cited 2019 Sep 29];77:1710–1719. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30269054
- Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmun Rev. [Internet]. 2017 cited 2019 Sep 28;16:1008–1015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28778702
- Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. [Internet]. 2017 cited 2019 Sep 29; 8:125–135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29184458
- Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. [Internet]. 2003;349:1907–1915. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14614165
- Maggi L, Cosmi L, Simonini G, et al. T cell subpopulations in juvenile idiopathic arthritis and their modifications after biotherapies. Autoimmun Rev. 2016;15:1141–1144. Elsevier B.V.
- Ruperto N, Lovell DJ, Tzaribachev N, et al. Subcutaneous abatacept in patients with polyarticular juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs: pharmacokinetics, efficacy and safety. Ann Rheum Dis. [Internet]. 2016;75:138.1–138. Available from: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-eular.1287
- Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383–391. (London, England) [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18632147
- Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. [Internet]. 2010;62:1792–1802. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20191582
- Blüml S, McKeever K, Ettinger R, et al. B-cell targeted therapeutics in clinical development. Arthritis Res Ther. [Internet]. 2013;Suppl 15:S4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23566679
- Eibel H, Kraus H, Sic H, et al. B cell biology: an overview. Curr Allergy Asthma Rep. 2014;14:434. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24633618
- Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163–1172. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21384257
- Alexeeva EI, Baranov A, Valieva SI, et al. Efficacy and safety of long-term rituximab use in patients with systemic juvenile idiopathic arthritis: the results of 5-year follow-up in real clinical practice. ACR meeting abstracts [Internet]. ACR/ARHP AnnuMeet. 2013 [cited 2020 Jan 3]. Available from: https://acrabstracts.org/abstract/efficacy-and-safety-of-long-term-rituximab-use-in-patients-with-systemic-juvenile-idiopathic-arthritis-the-results-of-5-year-follow-up-in-real-clinical-practice/
- Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100:782–786. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26396026
- van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. [Internet]. 2010 [cited 2020 Jan 7];62:75–81. Available from: http://doi.wiley.com/10.1002/art.25033
- Furer V, Rondaan C, Heijstek MW, et al. Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39–52.
- European Medicines Agency. Arcalyst. INN-Rilonacept [Internet]. [cited 2019 Sep 29]. Available from: https://ec.europa.eu/health/documents/community-register/2009/2009102366350/anx_66350_en.pdf.
- Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. [Internet]. 2013 cited 2019 Sep 29;65:2486–2496. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23754188
- Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (Interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58:2443–2452.
- European Medicines Agency. Kevzara. INN-Sarilumab [Internet]. [ cited 2019 Sep 29]. Available from: https://ec.europa.eu/health/documents/community-register/2017/20170623138002/anx_138002_en.pdf.
- A repeated dose-finding study of sarilumab in children and adolescents with systemic juvenile idiopathic arthritis (SKYPS). ClinicalTrials.gov [Internet]. [ cited 2020 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02991469.
- An open-label, ascending, repeated dose-finding study of sarilumab in children and adolescents with polyarticular-course juvenile idiopathic arthritis (pcJIA). ClinicalTrials.gov [Internet]. [cited 2020 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02776735
- De Benedetti F, Calvo Penadés I, Rubio-Pérez N. Sarilumab, a human monoclonal antibody to the interleukin-6 receptor, in polyarticular-course juvenile idiopathic arthritis: a 12-week, multinational, open-label, dose-finding study - [Internet]. ACR/ARP Annu Meet. 2019 [cited 2020 Jan 10]. Available from: https://acrabstracts.org/abstract/sarilumab-a-human-monoclonal-antibody-to-the-interleukin-6-receptor-in-polyarticular-course-juvenile-idiopathic-arthritis-a-12-week-multinational-open-label-dose-finding-study/
- European Medicines Agency. Stelara. INN-Ustekinumab [Internet]. [cited 2020 Jan 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.
- Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3. M Ann Rheum Dis. 2014;73:990–999.
- Mannion ML, McAllister L, Cron RQ, et al. Ustekinumab as a therapeutic option for children with refractory enthesitis-related arthritis. J Clin Rheumatol. 2016;22(5):282–284. Lippincott Williams and Wilkins.
- Kellen R, Silverberg NB, Lebwohl M. Efficacy and safety of ustekinumab in adolescents. Pediatr Heal Med Ther. [Internet]. 2016 [cited 2019 Sep 29];7:109–120. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29388600
- Canny S, Mellins E. New frontiers in the treatment of systemic juvenile idiopathic arthritis. F1000Res. 2017;6:2–9.
- Maggi L, Mazzoni A, Cimaz R, et al. Th17 and Th1 lymphocytes in oligoarticular juvenile idiopathic arthritis. Front Immunol Frontiers. 2019;10:450. Media S.A..
- Secukinumab safety and efficacy in JPsA and ERA. ClinicalTrials.gov [Internet]. [cited 2020 Jan 22]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03031782?term=CAIN457F2304&cond=secukinumab&draw=2&rank=1#studydesc.
- Foell D, Veit JA, Ilsley E, et al. AB1089 Investigation of the efficacy and safety of secukinumab treatment in juvenile idiopathic arthritis subtypes of juvenile psoriatic and enthesitis-related arthritis: design of a randomised, double-blind, placebo controlled, multicenter study. BMJ. 2018;77:1654.
- Foeldvari I, Baer J. Secukinumab is a promising treatment for patients with juvenile enthesitis related arthritis nonresponsive to anti-TNF treatment - [Internet]. ACR/ARP Annu Meet. 2019 [cited 2020 Jan 13]. Available from: https://acrabstracts.org/abstract/secukinumab-is-a-promising-treatment-for-patients-with-juvenile-enthesitis-related-arthritis-nonresponsive-to-anti-tnf-treatment/
- Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology. [Internet]. 2016 [cited 2019 Sep 29];55:2237–2247. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kew300
- Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis [Internet]. 2018 [cited 2019 Sep 29];77:annrheumdis-2017-212608. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29472362
- Lotito APN, Campa A, Silva CAA, et al. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol. [Internet]. 2007 [cited 2019 Sep 29];34:823–830. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17343316
- Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. [Internet]. 2010 [cited 2019 Sep 29];49:1645–1653. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20472718
- Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. [Internet]. 2012 [cited 2019 Sep 29];58:287–294. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22398373
- Vieira MC, Zwillich SH, Jansen JP, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clin Ther. 2016;38:2628–2641.e5.
- Kerrigan SA, McInnes IB. jak inhibitors in rheumatology: implications for paediatric syndromes?. Curr Rheumatol Rep. 2018; 20:83. Current Medicine Group LLC 1.
- Efficacy study of tofacitinib in pediatric JIA population. ClinicalTrials.gov [Internet] [cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT02592434.
- Long-term safety study of tofacinib in patients with juvenile idiopathic arthritis. ClinicalTrials.gov [Internet] [cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT01500551.
- A safety, efficacy and pharmacokinetics study of tofacitinib in pediatric patients with sJIA. ClinicalTrials.gov [Internet]. [ cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03000439.
- A study to evaluate the pharmacokinetics, safety, and tolerability of upadacitinib in pediatric subjects with polyarticular course juvenile idiopathic arthritis.. ClinicalTrials.gov [Internet]. [cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03725007.
- A study of baricitinib in participants from 2 years to less than 18 years old with juvenile idiopathic arthritis. ClinicalTrials.gov [Internet]. [cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03773978.
- A study of baricitinib (LY3009104) in participants from 1 year to less than 18 years old with sJIA. ClinicalTrials.gov [Internet]. [cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04088396.
- A study of baricitinib in participants from 1 year to less than 18 years old with juvenile idiopathic arthritis. ClinicalTrials.gov [Internet] [ cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03773965.
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. Internet]. 2012 [cited 2019 Sep 29];91:405–417. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22318617
- De Cock D, Kearsley-Fleet L, Davies R, et al. Biosimilar use in patients with juvenile idiopathic arthritis in a real-world setting in the United Kingdom. Am Coll Rheumatol. 2018;77(S2):485.2–485.
- Kok VC, Horng JT, Huang JL, et al. Population-based cohort study on the risk of malignancy in East Asian children with Juvenile idiopathic arthritis. BMC Cancer. 2014;14:634.
- Simard JF, Neovius M, Hagelberg S, et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. [Internet]. 2010 [cited 2020 Jan 26];62:3776–3782. Available from: http://doi.wiley.com/10.1002/art.27741
- Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. [Internet]. 2012 [cited 2020 Jan 26];64:1263–1271. Available from: http://doi.wiley.com/10.1002/art.34348
- Nordstrom BL, Mines D, Gu Y, et al. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res. (Hoboken) [Internet]. 2012 [cited 2020 Jan 26];64:1357–1364. Available from: http://doi.wiley.com/10.1002/acr.21709
- Beukelman T, Xie F, Chen L, et al. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. 2018;77:1012–1016.